# EDGAR Filing Document

**Accession Number:** 0001805890
**File Stem:** 0000000000-23-002828
**Filing Date:** 2023-3
**Character Count:** 3306
**Document Hash:** a9fdf25dc0f777b0a858324069bdf594
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-002828.hdr.sgml**: 20230420

**ACCESSION NUMBER**: 0000000000-23-002828

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230321

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Fusion Pharmaceuticals Inc.
- **CENTRAL INDEX KEY:** 0001805890
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** Z4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 270 LONGWOOD ROAD SOUTH
- **CITY:** HAMILTON
- **STATE:** A6
- **ZIP:** L8P 0A6
- **BUSINESS PHONE:** 289-799-0891

**MAIL ADDRESS:**
- **STREET 1:** 270 LONGWOOD ROAD SOUTH
- **CITY:** HAMILTON
- **STATE:** A6
- **ZIP:** L8P 0A6
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001193125-23-072555

## Text-Extract

```

United States securities and exchange commission logo

                        March 21, 2023

       Maria Stahl
       Chief Legal Officer
       Fusion Pharmaceuticals Inc.
       270 Longwood Road South
       Hamilton, Ontario, Canada, L8P 0A6

                                                        Re: Fusion
Pharmaceuticals Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed March 16,
2023
                                                            File No. 333-270604

       Dear Maria Stahl:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Jimmy
McNamara at 202-551-7349 with any questions.

                        Sincerely,

                        Division of Corporation Finance

                        Office of Life Sciences
       cc:                                              Mitchell S. Bloom

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

March 21, 2023

Maria Stahl
Chief Legal Officer
Fusion Pharmaceuticals Inc.
270 Longwood Road South
Hamilton, Ontario, Canada, L8P 0A6

**Re: Fusion Pharmaceuticals Inc.**
**Registration Statement on Form S-3**
**Filed March 16, 2023**
**File No. 333-270604**

Dear Maria Stahl:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jimmy McNamara at 202-551-7349 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Mitchell S. Bloom